Nutrition Intervention Trials in Linxian Follow-up Study
Launched by NATIONAL CANCER INSTITUTE (NCI) · Jun 19, 2006
Trial Information
Current as of October 03, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a long‑term follow‑up study of about 34,000 adults who took part in two large nutrition trials in Linxian, China (1985–1991) that looked at vitamins and minerals to help prevent esophageal and stomach cancers. The follow‑up is observational, meaning researchers will watch what happens over time to see cancer rates and overall deaths after the original trials ended, and to explore how nutrition, genetics, and the environment might relate to cancer and stroke. It’s not testing a new treatment, just gathering information to learn more from people who were in the earlier studies.
If you were part of the original Linxian trials, you may be invited to participate in this follow‑up. Eligible adults are 18 to 100 years old; the study uses non‑random, invitation‑based enrollment. The National Cancer Institute leads the project. Participants might be asked to complete interviews, nutrition surveys, and provide a blood sample for genetic and environmental research related to cancer and stroke. Again, no new medicine or device is being studied. The study is ongoing, with participation and data collection continuing toward an estimated completion in 2026.
Gender
ALL
Eligibility criteria
- • No eligibility criteria listed.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, China
Patients applied
Trial Officials
Christian C Abnet, Ph.D.
Principal Investigator
National Cancer Institute (NCI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials